Cargando…

Comparison of [(18)F]Flutemetamol and [(11)C]Pittsburgh Compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer's disease dementia individuals

BACKGROUND: Understanding the variation in uptake between different amyloid PET tracers is important to appropriately interpret data using different amyloid tracers. Therefore, we compared the uptake differences in [(18)F]Flutemetamol (FMT) and [(11)C]PiB (PiB) PET in the same people. METHODS: Struc...

Descripción completa

Detalles Bibliográficos
Autores principales: Lowe, Val J., Lundt, Emily, Knopman, David, Senjem, Matthew L., Gunter, Jeffrey L., Schwarz, Christopher G., Kemp, Bradley J., Jack, Clifford R., Petersen, Ronald C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5565786/
https://www.ncbi.nlm.nih.gov/pubmed/28856092
http://dx.doi.org/10.1016/j.nicl.2017.08.011
_version_ 1783258438259703808
author Lowe, Val J.
Lundt, Emily
Knopman, David
Senjem, Matthew L.
Gunter, Jeffrey L.
Schwarz, Christopher G.
Kemp, Bradley J.
Jack, Clifford R.
Petersen, Ronald C.
author_facet Lowe, Val J.
Lundt, Emily
Knopman, David
Senjem, Matthew L.
Gunter, Jeffrey L.
Schwarz, Christopher G.
Kemp, Bradley J.
Jack, Clifford R.
Petersen, Ronald C.
author_sort Lowe, Val J.
collection PubMed
description BACKGROUND: Understanding the variation in uptake between different amyloid PET tracers is important to appropriately interpret data using different amyloid tracers. Therefore, we compared the uptake differences in [(18)F]Flutemetamol (FMT) and [(11)C]PiB (PiB) PET in the same people. METHODS: Structural MRI, FMT PET and PiB PET were each performed in 30 young cognitively normal (yCN), 31 elderly cognitively normal (eCN) and 21 Alzheimer's disease dementia (AD) participants. PiB and FMT images for each participant were compared quantitatively using voxel- and region-based analyses. Region of interest (ROI) analyses included comparisons of grey matter (GM) regions as well as white matter (WM) regions. Regional comparisons of each tracer between different groups and comparisons of the two modalities within the different groups were performed. To compare mean SUVr between modalities, and between diagnostic groups, we used paired t-tests and Student's t-test, respectively. We also compared the ability of the two tracers to discriminate between diagnostic groups using AUROC estimates. The effect of using different normalization regions on SUVr values was also evaluated. RESULTS: Both FMT and PiB showed greater uptake throughout GM structures in AD vs. eCN or yCN. In all dual-modality group comparisons (FMT vs. PiB in yCN, eCN, and AD), greater WM uptake was seen with FMT vs. PiB. In yCN and eCN greater diffuse GM uptake was seen with FMT vs. PiB. When comparing yCN to eCN within each tracer, greater WM uptake was seen in eCN vs yCN. CONCLUSIONS: Flutemetamol and PiB show similar topographical GM uptake in AD and CN participants and the tracers show comparable group discrimination. Greater WM accumulation with FMT suggests that quantitative differences vs. PiB will be apparent when using WM or GM as a reference region. Both imaging tracers demonstrate increased WM uptake in older people. These findings suggest that using different amyloid tracers or different methods of analyses in serial brain imaging in an individual may result in artifactual amyloid change measurements. Clinical use of several amyloid tracers in the same patient will have challenges that need to be carefully considered.
format Online
Article
Text
id pubmed-5565786
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-55657862017-08-30 Comparison of [(18)F]Flutemetamol and [(11)C]Pittsburgh Compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer's disease dementia individuals Lowe, Val J. Lundt, Emily Knopman, David Senjem, Matthew L. Gunter, Jeffrey L. Schwarz, Christopher G. Kemp, Bradley J. Jack, Clifford R. Petersen, Ronald C. Neuroimage Clin Regular Article BACKGROUND: Understanding the variation in uptake between different amyloid PET tracers is important to appropriately interpret data using different amyloid tracers. Therefore, we compared the uptake differences in [(18)F]Flutemetamol (FMT) and [(11)C]PiB (PiB) PET in the same people. METHODS: Structural MRI, FMT PET and PiB PET were each performed in 30 young cognitively normal (yCN), 31 elderly cognitively normal (eCN) and 21 Alzheimer's disease dementia (AD) participants. PiB and FMT images for each participant were compared quantitatively using voxel- and region-based analyses. Region of interest (ROI) analyses included comparisons of grey matter (GM) regions as well as white matter (WM) regions. Regional comparisons of each tracer between different groups and comparisons of the two modalities within the different groups were performed. To compare mean SUVr between modalities, and between diagnostic groups, we used paired t-tests and Student's t-test, respectively. We also compared the ability of the two tracers to discriminate between diagnostic groups using AUROC estimates. The effect of using different normalization regions on SUVr values was also evaluated. RESULTS: Both FMT and PiB showed greater uptake throughout GM structures in AD vs. eCN or yCN. In all dual-modality group comparisons (FMT vs. PiB in yCN, eCN, and AD), greater WM uptake was seen with FMT vs. PiB. In yCN and eCN greater diffuse GM uptake was seen with FMT vs. PiB. When comparing yCN to eCN within each tracer, greater WM uptake was seen in eCN vs yCN. CONCLUSIONS: Flutemetamol and PiB show similar topographical GM uptake in AD and CN participants and the tracers show comparable group discrimination. Greater WM accumulation with FMT suggests that quantitative differences vs. PiB will be apparent when using WM or GM as a reference region. Both imaging tracers demonstrate increased WM uptake in older people. These findings suggest that using different amyloid tracers or different methods of analyses in serial brain imaging in an individual may result in artifactual amyloid change measurements. Clinical use of several amyloid tracers in the same patient will have challenges that need to be carefully considered. Elsevier 2017-08-14 /pmc/articles/PMC5565786/ /pubmed/28856092 http://dx.doi.org/10.1016/j.nicl.2017.08.011 Text en © 2017 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Regular Article
Lowe, Val J.
Lundt, Emily
Knopman, David
Senjem, Matthew L.
Gunter, Jeffrey L.
Schwarz, Christopher G.
Kemp, Bradley J.
Jack, Clifford R.
Petersen, Ronald C.
Comparison of [(18)F]Flutemetamol and [(11)C]Pittsburgh Compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer's disease dementia individuals
title Comparison of [(18)F]Flutemetamol and [(11)C]Pittsburgh Compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer's disease dementia individuals
title_full Comparison of [(18)F]Flutemetamol and [(11)C]Pittsburgh Compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer's disease dementia individuals
title_fullStr Comparison of [(18)F]Flutemetamol and [(11)C]Pittsburgh Compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer's disease dementia individuals
title_full_unstemmed Comparison of [(18)F]Flutemetamol and [(11)C]Pittsburgh Compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer's disease dementia individuals
title_short Comparison of [(18)F]Flutemetamol and [(11)C]Pittsburgh Compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer's disease dementia individuals
title_sort comparison of [(18)f]flutemetamol and [(11)c]pittsburgh compound-b in cognitively normal young, cognitively normal elderly, and alzheimer's disease dementia individuals
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5565786/
https://www.ncbi.nlm.nih.gov/pubmed/28856092
http://dx.doi.org/10.1016/j.nicl.2017.08.011
work_keys_str_mv AT lowevalj comparisonof18fflutemetamoland11cpittsburghcompoundbincognitivelynormalyoungcognitivelynormalelderlyandalzheimersdiseasedementiaindividuals
AT lundtemily comparisonof18fflutemetamoland11cpittsburghcompoundbincognitivelynormalyoungcognitivelynormalelderlyandalzheimersdiseasedementiaindividuals
AT knopmandavid comparisonof18fflutemetamoland11cpittsburghcompoundbincognitivelynormalyoungcognitivelynormalelderlyandalzheimersdiseasedementiaindividuals
AT senjemmatthewl comparisonof18fflutemetamoland11cpittsburghcompoundbincognitivelynormalyoungcognitivelynormalelderlyandalzheimersdiseasedementiaindividuals
AT gunterjeffreyl comparisonof18fflutemetamoland11cpittsburghcompoundbincognitivelynormalyoungcognitivelynormalelderlyandalzheimersdiseasedementiaindividuals
AT schwarzchristopherg comparisonof18fflutemetamoland11cpittsburghcompoundbincognitivelynormalyoungcognitivelynormalelderlyandalzheimersdiseasedementiaindividuals
AT kempbradleyj comparisonof18fflutemetamoland11cpittsburghcompoundbincognitivelynormalyoungcognitivelynormalelderlyandalzheimersdiseasedementiaindividuals
AT jackcliffordr comparisonof18fflutemetamoland11cpittsburghcompoundbincognitivelynormalyoungcognitivelynormalelderlyandalzheimersdiseasedementiaindividuals
AT petersenronaldc comparisonof18fflutemetamoland11cpittsburghcompoundbincognitivelynormalyoungcognitivelynormalelderlyandalzheimersdiseasedementiaindividuals